Novavax, Inc.
NASDAQ:NVAXBiotechnology
-$0.18 today
- Market cap
- $1.27B
- Beta
- 2.41
- P/E (TTM)
- -17.3
- EPS (TTM)
- -$0.54
Volume 4.34M
Average 4.58M
Returns on capital
Novavax, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-344.7%
avg 513.6%
ROIC
78.0%
avg -155.8%
ROA
37.4%
avg -42.2%
Analysis
ROIC is currently the strongest return metric at 78.0% versus its period average of -155.8%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
John Charles Jacobs | President, Chief Executive Officer & Director | USD 1.55M | 59 | — | — |
Mark Casey | Executive Vice President, Chief Legal Officer & Corporate Secretary | USD 984.26K | 63 | — | — |
Elaine O'Hara | Executive Vice President & Chief Strategy Officer | USD 947.01K | 58 | 112.67K | 0.07% |
James Patrick Kelly | Executive Vice President, Chief Financial Officer & Treasurer | USD 884.28K | 60 | 0 | <0.01% |
Ian J. Watkins | Executive Vice President & Chief Human Resources Officer | — | 63 | — | — |
Richard Crowley | Executive Vice President & Chief Operating Officer | — | 69 | — | — |
Troy Morgan | Senior Vice President, Deputy General Counsel & Chief Compliance Officer | — | 55 | — | — |
Erika S. Trahan | Associate Director of Investor & Public Relations | — | — | — | — |
Naina Zaman | Director of Investor Relations | — | — | — | — |
Silvia Taylor | Executive Vice President, Chief Corporate Affairs Officer & Head of Novavax Sweden | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 7, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | -15.2% (5yr)2 analysts |
| Revenue | N/A | N/A | -11.1% | -16.9% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | -15.2% (5yr)3 analysts |
| EBIT | N/A | N/A | N/A | -14.1% (5yr)3 analysts |
Analysis
Recent growth has been strongest in Revenue at -11.1% over three years. Forward estimates point to EBIT at -14.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Novavax, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about NVAX's management, answered from reported figures.
Who manages NVAX?
Novavax, Inc. (NVAX) lists 10 active executives. The top listed executive is Ian J. Watkins, Executive Vice President & Chief Human Resources Officer.
Are NVAX insiders buying or selling?
Recent insider activity shows net buying of $34.36M.
Continue the stock analysis
Jump to another research area for this company.